103 related articles for article (PubMed ID: 17945033)
1. The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
Grothey E; Chu E
Clin Colorectal Cancer; 2007 Sep; 6(9):621-4. PubMed ID: 17945033
[No Abstract] [Full Text] [Related]
2. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
de Melo JV; Vieira de Melo MS; Abad MH
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
[TBL] [Abstract][Full Text] [Related]
3. Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.
Ozen A; Cicin I; Sezer A; Uzunoglu S; Saynak M; Genchellac H; Karagol H
J Cancer Res Ther; 2009; 5(2):130-2. PubMed ID: 19542672
[TBL] [Abstract][Full Text] [Related]
4. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
6. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
7. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
[TBL] [Abstract][Full Text] [Related]
8. Sequential or combination chemotherapy for a patient with mCRC?
Arnold D
Cancer Treat Rev; 2008; 34 Suppl 2():S12-6. PubMed ID: 19101403
[TBL] [Abstract][Full Text] [Related]
9. [mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Kuwabara H; Baba H; Wakabayashi M; Nakamura H; Sanada T; Baba H; Nakajima K; Goseki N
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2250-2. PubMed ID: 22202345
[TBL] [Abstract][Full Text] [Related]
10. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
[No Abstract] [Full Text] [Related]
12. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
13. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
14. [A case of undifferentiated colon cancer responding to FOLFIRI therapy].
Fujiwara K; Nagayoshi Y; Nakahara C; Yamasaki T; Iwashita T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1525-7. PubMed ID: 21918355
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
19. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
20. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Allen JA; Adlakha A; Bergethon PR
Arch Neurol; 2006 Oct; 63(10):1475-8. PubMed ID: 17030665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
